Descripción de la empresa
CeriBell, Inc. operates as a specialized medical technology firm within the United States, focusing on the development and deployment of the Ceribell System. This innovative point-of-care EEG platform is engineered to address critical diagnostic needs for patients situated in acute care environments, offering disposable and flexible headbands alongside its core system. The company functions within the Healthcare sector and specifically the Medical Devices industry, positioning itself at the intersection of advanced diagnostics and patient care infrastructure. With a market capitalization of $672.65M and annual revenue of $89.06M, CeriBell, Inc. demonstrates a significant scale relative to many niche medical device peers. Operating with a workforce of 327 employees, the entity has established a substantial operational footprint that suggests a mature yet aggressive growth phase in the medical technology landscape. The valuation figures indicate that the market assigns a premium multiple to the company's intellectual property and potential, reflecting high expectations for the commercialization of its proprietary EEG technology.
Salud financiera
The financial statements for CeriBell, Inc. reveal a revenue stream of $89.06M over the trailing twelve months, contrasted against a net income of $-53,412,000 and an EBITDA of $-57,061,000. The substantial gap between the positive revenue and the negative net income highlights a heavy cost structure, likely driven by research and development expenditures or significant operating costs inherent in launching novel medical devices. The company reported a free cash flow of $-23,596,500, indicating a current consumption of cash that necessitates a robust liquidity reserve to sustain operations during this investment-intensive period. Analysis of the margins shows a gross margin of 87.9%, which reflects highly efficient production and strong pricing power typical of proprietary medical technologies. However, the operating margin stands at -58.9% and the profit margin at -60.0%, signaling that general and administrative expenses are currently outpacing gross profits as the company scales its market presence. Regarding capital structure, the company holds $159.26M in cash against $22.28M in debt, resulting in a debt-to-equity ratio of 14.34. Despite the high debt-to-equity figure, the absolute level of cash far exceeds debt obligations, suggesting a conservative balance sheet posture regarding solvency risk. The current ratio is 9.73, which indicates an exceptionally strong short-term liquidity position providing ample coverage for immediate liabilities. Return on Equity is recorded at -30.8% and Return on Assets at -17.3%, metrics that reveal management is currently deploying capital to generate future growth rather than immediate shareholder returns, consistent with the company's stage of development.
Evaluación de valoración
Valuation metrics for CeriBell, Inc. present a complex picture due to the lack of positive earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -17.77. The negative forward P/E implies that the market expects earnings to turn positive in the future or that the current valuation model relies heavily on revenue growth rather than current profitability. The price-to-book ratio is 4.31, indicating that the market values the company at more than four times its net asset value, suggesting a significant premium assigned to its intangible assets and technology. Alternative valuation measures include a price-to-sales ratio of 7.55 and an EV/EBITDA of -9.39, which suggest the market is pricing the stock based on future revenue potential and growth prospects rather than current cash flow generation. The stock has traded between a 52-week high of $24.33 and a 52-week low of $10.01. Without the current specific share price listed in the provided facts, the precise percentage deviation from the high or low cannot be calculated, but the range demonstrates substantial volatility within the year. The beta value is listed as N/A, which implies that the stock's price volatility relative to the broader market is either not statistically significant enough to calculate or that the data point is unavailable for this specific reporting period.
Growth & Income
CeriBell, Inc. demonstrated robust top-line expansion with a revenue growth rate of 33.7% year-over-year, while earnings growth is listed as N/A due to the company's current net loss status. The divergence between strong revenue expansion and negative earnings growth is typical for medical device companies in the growth phase, where significant capital is directed toward R&D and market penetration rather than immediate profit generation. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are theoretically reinvested into business growth or used to fund operations, though currently, no dividends are distributed. The overall growth and income profile is characterized by high revenue velocity paired with a zero-dividend strategy, prioritizing long-term technological advancement over current income distribution to shareholders. This financial structure aligns with the strategic imperative of a medical device firm seeking to capture market share in the acute care EEG space before achieving sustained profitability.